These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 30407890)
21. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Greig SL; Deeks ED Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405 [TBL] [Abstract][Full Text] [Related]
22. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R; J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922 [TBL] [Abstract][Full Text] [Related]
24. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466 [TBL] [Abstract][Full Text] [Related]
25. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops. Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653 [TBL] [Abstract][Full Text] [Related]
26. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302 [TBL] [Abstract][Full Text] [Related]
27. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety]. Kurysheva NI Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546 [TBL] [Abstract][Full Text] [Related]
28. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV; Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072 [TBL] [Abstract][Full Text] [Related]
29. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Chevrier RL; Assalian A; Duperré J; Lesk MR Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253 [TBL] [Abstract][Full Text] [Related]
30. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment]. Titouamane S; Baudouin C J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942 [TBL] [Abstract][Full Text] [Related]
31. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi FJ; Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288 [TBL] [Abstract][Full Text] [Related]
32. α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model. Jung KI; Kim JH; Park CK Eur J Pharmacol; 2015 Oct; 765():274-83. PubMed ID: 26300392 [TBL] [Abstract][Full Text] [Related]
33. Brinzolamide plus brimonidine for the treatment of glaucoma: an update. Chew SK; Skalicky SE; Goldberg I Expert Opin Pharmacother; 2014 Nov; 15(16):2461-71. PubMed ID: 25267543 [TBL] [Abstract][Full Text] [Related]
34. Side-effect profile of brimonidine tartrate in children. Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927 [TBL] [Abstract][Full Text] [Related]
35. Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group. Ophthalmic Surg Lasers; 1995; 26(5):404-9. PubMed ID: 8963853 [TBL] [Abstract][Full Text] [Related]
36. Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma. Mizoue S; Nitta K; Shirakashi M; Nitta A; Yamabayashi S; Kimura T; Ueda T; Takeda R; Matsumoto S; Yoshikawa K Adv Ther; 2017 Jun; 34(6):1438-1448. PubMed ID: 28508306 [TBL] [Abstract][Full Text] [Related]
37. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)]. Detry-Morel M; Dutrieux C J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496 [TBL] [Abstract][Full Text] [Related]
39. [Alpha-2 adrenergic agonists in the treatment of glaucoma]. Apătăchioae I; Chiseliţă D Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099 [TBL] [Abstract][Full Text] [Related]
40. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. Liu CJ; Cheng CY; Ko YC; Hsu WM J Chin Med Assoc; 2004 Sep; 67(9):465-71. PubMed ID: 15617307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]